CJ 13610: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9821945 |
| CHEMBL ID | 195309 |
| SCHEMBL ID | 332442 |
| MeSH ID | M0481204 |
| Synonym |
|---|
| 4-[3-[4-(2-methylimidazol-1-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide |
| cj 13610 |
| cj-13,610 |
| bdbm50166596 |
| 4-(3-(4-(2-methyl-1h-imidazol-1-yl)phenylthio)phenyl)tetrahydro-2h-pyran-4-carboxamide |
| 4-{3-[4-(2-methyl-imidazol-1-yl)-phenylsulfanyl]-phenyl}-tetrahydro-pyran-4-carboxylic acid amide |
| CHEMBL195309 , |
| NCGC00248040-01 |
| 179420-17-8 |
| cj-13610 , |
| 4-(3-{[4-(2-methyl-1h-imidazol-1-yl)phenyl]sulfanyl}phenyl)oxane-4-carboxamide |
| cj13610 |
| gtpl5169 |
| 2h-pyran-4-carboxamide, tetrahydro-4-(3-((4-(2-methyl-1h-imidazol-1-yl)phenyl)thio)phenyl)- |
| 5275PJ1C59 , |
| 4-(3-((4-(2-methyl-1h-imidazol-1-yl)phenyl)sulfanyl)phenyl)tetrahydro-2h-pyran-4-carboxamide |
| SCHEMBL332442 |
| 4-{3-[4-(2-methyl-imidazol-1-yl)-phenyl sulfanyl]-phenyl}tetrahydro-pyran-4-carboxylic acid amide |
| VPTONMHDLLMOOV-UHFFFAOYSA-N , |
| 4-[3-[4-(2-methylimidazol-1-yl)phenylthio]phenyl]-3,4,5,6-tetrahydro-2h-pyran-4-carboxamide |
| unii-5275pj1c59 |
| DTXSID7047273 |
| 4-(3-{[4-(2-methyl-1h-imidazol-1-yl)phenyl]sulfanyl}phenyl)tetrahydro-2h-pyran-4-carboxamide |
| AC-31477 |
| AKOS030537488 |
| cj-13610, >=98% (hplc) |
| Q27076088 |
| 2h-pyran-4-carboxamide, tetrahydro-4-[3-[[4-(2-methyl-1h-imidazol-1-yl)phenyl]thio]phenyl]- |
| HMS3867L03 |
| 4-(3-((4-(2-methyl-1h-imidazol-1-yl)phenyl)thio)phenyl)tetrahydro-2h-pyran-4-carboxamide |
| HY-106200 |
| CS-0025218 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of the compound following the colon administration in dogs, relative to the same formulation administered orally (relative bioavailability), was determined." | ( Dog colonoscopy model for predicting human colon absorption. Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006) | 0.33 |
| "Except for atenolol, a small hydrophillic molecule, the relative bioavailability from administration to the colon of the dog correlated well with the following compound properties: high solubility and high, passive permeability > high solubility, low permeability > low solubility, high, passive permeability approximately low solubility, low permeability." | ( Dog colonoscopy model for predicting human colon absorption. Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006) | 0.33 |
| " However, no human intubation or dog colon studies are required for Class 1 (HS/HP), as these compounds are likely to be well absorbed from the colon." | ( Dog colonoscopy model for predicting human colon absorption. Evans, LA; Fortner, JH; McCarthy, JM; Sutton, SC; Sweeney, K, 2006) | 0.33 |
| "The following recommendations are made regarding intubation studies: (i) no intubation study is recommended for compounds with high permeability, since these compounds are likely to be well absorbed from the colon; (ii) compounds with moderate permeability may require an intubation study if the dog colon and in silico models predict a marginally acceptable CR concentration-time profile; (iii) use a dose that approximates 1 h of the intended CR delivery rate; (iv) use the smallest volume possible; (v) define and record tubing placement; (vi) use a thermodynamically stable solution or/and suspension." | ( The use of gastrointestinal intubation studies for controlled release development. Sutton, SC, 2009) | 0.35 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the rat air pouch model, oral dosing of CJ-13,610 and zileuton resulted in selective inhibition 5-LOX activity from pouch exudate and ex vivo rat whole blood with similar potency to in vitro assay." | ( A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Anderson, GD; Dufield, DR; Hardy, MM; Masferrer, JL; Pufahl, RA; Zweifel, BS, 2008) | 0.35 |
| " Also included are human pharmacokinetic studies with prototype CR dosage forms for CJ-13,610 and CP-424,391." | ( The use of gastrointestinal intubation studies for controlled release development. Sutton, SC, 2009) | 0.35 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID248045 | Inhibition of 5-lipoxygenase mediated LTB4 synthesis in A-23187 simulated human whole blood | 2005 | Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10 | 5-Lipoxygenase inhibitors: convenient synthesis of 4-[3-(4-heterocyclylphenylthio)phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide analogues. |
| AID246905 | Inhibition of 5-lipoxygenase-mediated platelet activating factor induced thrombosis in male mice | 2005 | Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10 | 5-Lipoxygenase inhibitors: convenient synthesis of 4-[3-(4-heterocyclylphenylthio)phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide analogues. |
| AID461096 | Inhibition of potato tuber 5LOX by polarographic method | 2010 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 | Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors. |
| AID1345233 | Human 5-LOX (Lipoxygenases) | 2004 | British journal of pharmacology, Jul, Volume: 142, Issue:5 | Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||